# Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients

> **NCT00621361** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 62 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** AZD2171
- **DRUG:** Etoposide
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT00621361
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2009-08
- **Final completion:** 2012-02
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2012-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00621361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00621361, "Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT00621361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*